Drug against cancer has treated a rare blood disease Swiss pharmaceutical company

Alent Swiss pharmaceutical company that the drug Gleevec anti-cancer could be very useful in the of a rare disease that affects the blood and makes the body over-production of white blood cells.  A study published in the British Medical Journal (Lancet) that four out of every five people with symptoms of increased pellets easy pigmentation Baloiosen responded positively to the drug Gleevec, which is produced by Novartis. Cancer Specialist said company Novartis David Parkinson, said his company and verify relay activity is possible in this topic. And got drug Gleevec approval for use in more than 60 countries for the treatment of chronic myeloid leukemia. And have been approved for use of the property in the United States and Switzerland for the treatment of intestinal tumors textile. The drug Gleevec sales reached in the first quarter of this year 183 million Swiss francs ($ 113.86 million).  And given the drug Gleevec anti-cancer usually for patients with advanced stages of leukemia or blood cancer, and is used as a drug against chronic myeloid leukemia. It is noteworthy that chronic myeloid leukemia - which affects in the habit of encroached middle age - is a disease of the bone marrow and leads to excessive production of blood cells, and after nearly five years of chronic phase enters disease last stages that usually lead to death of the patient during the a period of between two and six months.

-->